Evaluation of the Quality of Adjuvant Endocrine Therapy Delivery for Breast Cancer Care in the United States

Daly, Bobby; Olopade, Olufunmilayo I.; Hou, Ningqi; Yao, Katharine; Winchester, David J.; Huo, Dezheng

doi:10.1001/jamaoncol.2016.6380

Cited by 28 publications

(24 citation statements)

References 60 publications

(75 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tamoxifen is a treatment option for both pre‐menopausal and post‐menopausal women (Early Breast Cancer Trialists’ Collaborative Group, ). Despite the prognostic benefits of ET, the adherence to treatment varies, and 30%–70% of the patients discontinue their treatment within 5 years (Daly et al, ; Tinari et al, ; Ursem et al, ). Non‐adherence mainly occurs during their first year of treatment (He et al, ), partly because ET is associated with several adverse side effects, such as hot flashes, depression, nausea and oedema (Regan, Price, Giobbie‐Hurder, Thürlimann, & Gelber, ).…”

Section: Introductionmentioning

confidence: 99%

“…Tamoxifen is a treatment option for both pre-menopausal and post-menopausal women (Early Breast Cancer Trialists' Collaborative Group, 2011). Despite the prognostic benefits of ET, the adherence to treatment varies, and 30%-70% of the patients discontinue their treatment within 5 years (Daly et al, 2017;Tinari et al, 2015;Ursem et al, 2015). Non-adherence mainly occurs during their…”

mentioning

confidence: 99%

See 1 more Smart Citation

“It is not just any pill”—Women’s experiences of endocrine therapy after breast cancer surgery

et al. 2019

View full text Add to dashboard Cite

Objective For patients diagnosed with hormone‐receptor‐positive breast cancer, endocrine therapy (ET) is usually prescribed to reduce recurrence and mortality rates. Despite the benefits, compliance with treatment varies. The aim of this study was to provide qualitative data about women's experiences with ET after breast cancer surgery. Methods Twenty‐five women, treated with Tamoxifen after breast cancer surgery, were interviewed in seven focus groups. Six open‐ended questions were used to explore their experiences. The interviews were recorded, transcribed verbatim and analysed using inductive content analysis. Results The analysis resulted in three categories that described the women's experiences: the treatment “creates discomfort”; “promotes levels of management”; and “causes feelings of abandonment”. Women's experiences of treatment could at first glance be seen as positive, as perceived protection, but after further analysis, a deeper meaning was identified: protection with reservation. When experiencing discomfort, the women tried to manage the situation, although the mode of management sometimes varied. The women reported that they needed support, but when the support did not appear, they felt as though they had been abandoned. Moreover, knowledge about side effects became an obstacle, as it could create fear of more severe symptoms. They also described that their disease was perceived by healthcare professionals as “cancer light”. Conclusion The information needs to be customised specifically to each person.

show abstract

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

“It is not just any pill”—Women’s experiences of endocrine therapy after breast cancer surgery

et al. 2019

View full text Add to dashboard Cite

show abstract

“…However, the adherence and persistence to hormonal treatment has been shown repeatedly to be low in clinical practice, with < 50–70% of HR positive disease patients receiving adjuvant hormonal therapy during the period our patients were evaluated [32]. Even more recent publications continue to show the same pattern of lower adherence to adjuvant hormonal therapy, especially in patients < 40 yo [33]. Current guidelines advocate hormone therapy for all young patients with HR positive tumors [34].…”

Section: Discussionmentioning

confidence: 97%

Analysis of breast cancer in young women in the Department of Defense (DOD) database

Zimmer

Zhu

Steeg

et al. 2017

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…Several of the highest priority research gaps centered on improving delivery of care, including interventional studies to improve adherence to medication. This ranked highly in part because it is common, negatively impacts outcome, and in particular affects vulnerable breast cancer patients such as African-American (36–38) and women at both ends of the age spectrum. (36, 39–42).…”

Section: Overview Of This Ccr Focusmentioning

confidence: 99%

“…This ranked highly in part because it is common, negatively impacts outcome, and in particular affects vulnerable breast cancer patients such as African-American (36–38) and women at both ends of the age spectrum. (36, 39–42). Comparative effectiveness, namely the comparison of existing approaches to determine greatest benefits and harms, was also felt to be an understudied topic, and one ripe for the cooperative group setting since these are difficult to fund studies outside of the federal sphere, and often have substantial public policy implications.…”

Section: Overview Of This Ccr Focusmentioning

confidence: 99%

Unmet Needs in Clinical Research in Breast Cancer: Where Do We Need to Go?

Partridge

Carey

2017

Clinical Cancer Research

View full text Add to dashboard Cite

This CCR Focus highlights areas in breast cancer research with the greatest potential for clinical and therapeutic application. The six articles in the issue address the state of the science in a broad range of areas with a focus on “hot” though sometimes controversial topics, unanswered questions, and unmet need. From mutational signatures, the cancer genomic revolution, and new inroads in immunotherapy for breast cancer, to unique concerns of vulnerable populations as well as national and global health disparities, these works represent much of the promise of breast cancer research as well as the challenges in the coming years. Each review focuses not only on recent discoveries, but also putting the topic in context including limitations to overcome. This overview is designed to further contextualize the highlighted issues within the broader research landscape. We also present new information from a poll of ALLIANCE for Clinical Trials in Oncology Breast Committee members regarding the most needed and viable potential future NCI-supported clinical trials in breast cancer. The great challenge is to translate the potential benefits of greater scientific knowledge reflected in this Focus series into improvements in outcomes for individuals and populations with breast cancer. A unifying theme across the six articles contained in this CCR Focus is the increasingly recognized value and necessity of collaboration across disciplines from bench to bedside to populations. Only continued and iteratively amplified scientific, clinical and governmental commitment to creating, testing, and implementing new knowledge will reduce the global morbidity and mortality of breast cancer.

show abstract

Evaluation of the Quality of Adjuvant Endocrine Therapy Delivery for Breast Cancer Care in the United States

Cited by 28 publications

References 60 publications

“It is not just any pill”—Women’s experiences of endocrine therapy after breast cancer surgery

“It is not just any pill”—Women’s experiences of endocrine therapy after breast cancer surgery

Analysis of breast cancer in young women in the Department of Defense (DOD) database

Unmet Needs in Clinical Research in Breast Cancer: Where Do We Need to Go?

Contact Info

Product

Resources

About